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Abstract 
 
Background: Little is known about non-terminally ill cystic fibrosis (CF) patients who die by 
voluntary cessation of therapy. The current study was undertaken to provide an international 
snapshot of this problem. 
Methods: An online survey was distributed to the medical directors of the CF Centres 
affiliated with the US Cystic Fibrosis Foundation and Cystic Fibrosis Australia (with the 
inclusion of New Zealand); the same letter was sent to every clinician member of the 
European Cystic Fibrosis Society. 
Results: More than 200 patients were reported as being in the situation described above. 
Data analysis was eligible in 102 patients (4 children, 25 adolescents and 73 adults). 92% 
were capable of judgement. Time-consuming and low immediate-impact therapies, such as 
respiratory physiotherapy, were most frequently discontinued first. Resignation was the main 
reported reason, followed by reactive depression and lack of familial support. 69% received 
palliative care and 72% died in the six months following refusal. 
Conclusions: Death of non-terminally ill CF patients due to voluntary cessation of therapy 
exists. This challenging situation should be discussed in multi-disciplinary teams so that the 
most appropriate attitude, suited to the individual situation, is defined. 
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Background: 
Although recent advances have dramatically lengthened the average life span of 
people with cystic fibrosis (CF), the disease retains its distinctive clinical trajectory: periods of 
intermittent pulmonary exacerbation requiring intensive therapy followed by periods of 
relative disease quiescence which still require active (1–5) and time-consuming daily therapy 
(1, 6–9). As the disease progresses, there is rarely a clear signal for the transition from this 
pattern of acute care to a palliative care approach (10–12). For a seriously ill patient, each 
pulmonary exacerbation might be the one during which death occurs, but there might also be 
a return to baseline. This fundamental uncertainty can lead to the habit of aggressive in-
hospital care (2,10–15) at a time when similarly ill patients with other disease trajectories, 
such as end-stage cancer, might be offered palliative care in non-hospital settings (2,10–13). 
Even when experiencing periods of being in a relatively stable condition, patients with CF 
must maintain a strikingly complex and time-consuming daily regimen. Adherence to this 
regimen is difficult even in times of relative health. As the patients’ clinical conditions 
deteriorate, maintenance of this regimen, with often little chance of an observable clinical 
effect, becomes more burdensome. In particular, maintenance of daily respiratory 
physiotherapy (RP) can be challenging (1, 3–7, 9,16–21).  
 The combination of an uncertain disease trajectory without a clear signal for initiation 
of palliative care and burdensome, and only partially symptom-relieving, daily therapy can 
lead to substantial drops in adherence. Several cases became known to one of the authors 
(GH), in which CF patients appeared to decide to stop their daily treatments partially or 
completely in recognition of their perceived hopelessness or futility. Medical literature is 
virtually silent on patients taking this step: a challenging situation for a multi-disciplinary CF 
team.  
 The current study was undertaken to provide an international snapshot of this 
problem, as well as to get some preliminary (and potentially hypothesis-generating) data on 
clinicians’ views of this topic. Our aim was to gather quantitative and qualitative data from 
clinicians about CF patients who died after choosing to interrupt their treatments, in order to 
improve medical practice and initiate further discussion on this difficult subject. 
 
Methods:  
 An informative letter describing the study and containing a web link to an online 
survey was distributed by e-mail to the medical directors of the CF Centres affiliated with the 
US Cystic Fibrosis Foundation (CFF, n=250) and Cystic Fibrosis Australia (CFA) (with the 
inclusion of New Zealand, n= 45); the same letter was sent to every clinician member of the 
European Cystic Fibrosis Society (ECFS, n=723).  
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The questionnaire was sent in August 2013 to the CFF and CFA, in September 2013 
to the ECFS and in October 2013 to New Zealand. A reminder to complete the survey was 
sent 3–8 weeks after the first delivery to enhance response rates. The link for the online 
questionnaire was closed at the end of November 2013. 
The study was approved by the local ethics committee of the University of Lausanne 
in Switzerland (Study protocol 107/13). 
The questionnaire (text in the online supplement) began with preliminary questions 
concerning the location of the clinic and the ages of the patients cared for there 
(paediatric/adolescent, adult, all ages); clinicians were then asked to report on their 
understanding of the law regarding voluntary refusal of treatment in their jurisdiction. To 
include a patient(s), the following “inclusion question” (Question 6) had to be answered with 
“yes”: “Have you ever had a CF patient (whom you did not consider terminal) tell you that 
he/she has decided to stop all or most of his/her treatments because of a wish to stop 
fighting the disease? Or have you ever suspected that a patient (whom you did not consider 
terminal) was discontinuing all or most of his/her CF treatments as part of a desire to die?” If 
“no” was ticked, the survey concluded. If a case(s) was/were known, then additional 
questions concerning the case(s) were asked: in particular concerning the patient’s 
judgemental ability; the patient’s age and disease severity at the time of the voluntary refusal; 
the identity of the decision-maker; the duration of survival after the refusal; the order in which 
treatments were stopped; the use of palliative care; and the reasons of stopping care. It was 
possible to enter data only for three patients per questionnaire and the participants had the 
choice to remain anonymous or give their location.  
We only included the fully completed questionnaires of patients who gave a positive 
answer to the “inclusion question” in this analysis. We did not further analyse incomplete 
surveys with a positive response to the inclusion question because of high heterogeneity and 
variability. Patients who were still alive at the completion of the survey were also excluded.  
 
Analysis: 
 Patient age was categorised for analysis as follows: children (0–13 years), 
adolescents (14–17 years) and adults (18 years or over).  
 The most interesting themes and questions were selected and presented below 
following the application of a univariate analysis. 
 Response errors resulting from respondent data-entry mistakes limited the 
interpretation of some items of the completed surveys: the results for such items (Table 2) 
were therefore presented with regard to the interpretable responses as follows: number of 
interpretable responses/all the responses (e.g. 25/27).   
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Results: 
231 clinicians returned the survey (a response rate of 22.7%; 231 responses/1,018 
participants solicited), with at least 204 patients for whom the inclusion question was 
reported positive. 100 participants (100/231 or 43.3%) indicated that they have had patients 
who have stopped treatment: 28 participants (28%) had one patient, 37 participants (37%) 
had two patients, nine participants (9%) had three patients, 25 participants (25%) had more 
than three patients and one participant (1%) had an unknown number of patient(s) in this 
situation. Among these 204 patients, only 102 were eligible for analysis. For the other half, 
the inclusion question was answered positively but the clinicians stopped filling in the 
questionnaire.  
Of these 102 patients, four were children (3.9%), 25 were adolescents (24.5%) and 
73 were adults (71.6%) at the time of death. 71 were from the United States, 16 from Europe 
and 15 from Australia (see Table 1). 
Most patients were considered by clinicians to be capable of judgement in order to 
voluntarily refuse care (94/102; 92.2%). Of the eight patients who were not considered to be 
capable of judgement (8/102; 7.8%), one was a child, six were adolescents and one was an 
adult. The mean age at which the refusal of care was made was 12 years for children, 16 
years for adolescents, 25 years for adults and 22 years when the overall results were 
considered irrespective of age category.  
 In most cases, the decision to stop treatment was made by the patients themselves 
(98/102; 96.1%). In the remaining four patients (3.9%), both parents made the decision for 
the two children in this group and respectively the mother or the spouse in the case of the 
two adult patients. Of those four patients, one adult and one child, who were capable of 
judgement, had made advanced directives. 
The mean age at death was 13.5 years for children, 17 years for teenagers, 26 years 
for adults and 23 years when the overall results were considered irrespective of age 
category. The difference between the mean age at the time of the decision and death – the 
overall survival time – was available in a total of 88 patients: it was less than 1 month in 23 
patients, 1 to 2 months in 15 patients, 3 to 4 months in 10 patients, 5 to 6 months in 15 
patients, 7 to 8 months in 2 patients, 9 to 10 months in 3 patients, 11 to 12 months in 7 
patients and longer than a year in 13 patients. In other words, 72% of patients died during 
the six months following refusal. 
Based mainly on the FEV1 and/or BMI for 79% of all patients (81/102), the 
respondents considered the severity of the disease to be severe. The rest of the patients 
were classified as having an intermediate-severe disease (18/102; 18%) or a mild disease 
(3/102; 3%). In the sub-group of children, 75% were considered to have an intermediate-
severe disease (3/4) and one child (25%) to be severely ill. In the sub-group of adolescents, 
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80% (20/25) were considered to be severely ill while the rest of the patients (5/25; 20%) 
were considered to have a mild disease. 
Over half of the patients died in hospital (53/102; 52%); 44 patients died at home 
(44/102; 43.1%); one adolescent (1/102; 1%) died in a hospice and the location of death for 
four adult patients (4/102 or 3.9%) was unknown to the respondents. In the sub-group 
analysis: two children died in hospital and two at home, twelve adolescents died at home and 
twelve in hospital with one in a hospice and 39 adults died in hospital (53.4%) against 30 at 
home (41.1%).   
The treatment regimen was stopped progressively by 73 patients (73/102; 71.6%), 
while 29 patients stopped it all at once (29/102; 28.4%), (see Table 2). For the patients that 
stopped treatments progressively, the most common sequence was to stop physiotherapy, 
antibiotics (oral or IV, not specified) or vitamins first, and pancreatic enzymes, diet or 
antibiotics last. These results are similar in the different age categories. Of the patients who 
stopped treatment progressively, some resumed taking various aspects of the regimen after 
the initial decision to refuse them (31/72; 43.1%). Antibiotics and pancreatic enzymes were 
the treatments most often resumed by adults, whereas in adolescents, the resumed 
treatments were more commonly pancreatic enzymes and dietary changes. 
Of all the 102 patients, 70 (69%) received and/or accepted palliative care: 48/73 
adults (66%), 19/25 adolescents (76%) and 3/4 children (75%) (see Table 3). Opioids and 
oxygen were given to almost all patients who received/accepted palliative care. Non-opioid 
analgesics and non-invasive ventilation were less frequently used alternatives. Anxiolytics 
followed by benzodiazepines and anti-nausea/anti-emetics are other palliative treatments 
that were frequently administered. Anti-spasmodics/spasmolytics were the least-used 
treatments. 
The clinicians’ reports about the patients’ reasons for stopping or decreasing therapy 
is detailed in Tables 4 and 5. As Table 4 indicates, in the majority of cases, clinicians 
reported that the reasons for the patients’ decisions were complex and overlapping; when 
asked to choose one primary main reason, clinicians most frequently reported that they 
assessed the patients as having concluded that “the disease will always have the upper 
hand” (resignation) (29/102; 28.4%) and “enough is enough/discontent regarding the 
treatments” (25/102; 24.5%). These reasons were followed by “reactive depression” in the 
adult sub-group (10/73; 13.7%) and “dysfunctional family and support” in the adolescent sub-
group (6/25; 24%). 33 (33%) of the 39 patients assessed as having reactive depression were 
not reported as having received any specific therapy for this condition: the majority were 
adults (10/13; 77%), the rest were adolescents (3/13; 23%). 
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Discussion 
Although the topic is largely absent in the literature, our results demonstrate that voluntary 
cessation of treatment in CF does exist: this research, while preliminary, uncovered at least 
204 clinician reports of patients across three continents who voluntarily altered some or all 
aspects of CF treatment, presumably leading to shortened survival.  
Our findings imply that there is, for many patients and clinicians, a time of resignation 
in which the burdens of the treatment regimen outweigh the perceived benefits. While the 
precise time of death is unpredictable (2,10–12,14), there may be a consensus between the 
patient and the clinician, even if only a tacit one, that the end of life is near enough to make 
changes to the regimen. This may be a sudden and striking change in the pattern of care for 
the CF patient for whom the importance of adherence to treatment has been an overriding 
theme since diagnosis, or it may be a more subtle shift towards a different perception of the 
“costs and benefits” of maintaining good adherence.  
As found in the literature (5, 6, 21–23), our results suggest that changes in the 
regimen were based on the perceived burden and short-term lack of benefit of the therapy 
from the patient’s perspective. RP was the most common treatment discontinued. This is no 
surprise as it is the most time-consuming and tiresome therapy in the patients’ perception. It 
requires active patient collaboration and is known to have the lowest adherence rate (50% in 
the best cases) combined with difficulty in measuring the short-term benefits (1, 3–7, 9, 16–
24). Low-burden but high immediate-impact therapies, such as oral pancreatic enzymes (6, 
21–23), were more likely to be continued or resumed. This pattern indicates that patients with 
CF and maybe CF clinicians, most likely in recognition of the nearness of death and the lack 
of short-term efficacy of standard CF therapies, are shifting to a model of comfort care in 
which therapies are judged appropriate by their ability to simply relieve symptoms.  
We could expect that this shift in the approach to care might be accompanied by the 
explicit use of palliative care. This was the case in the majority of patients described by the 
clinician respondents, but not all. Medications to relieve the symptoms of dyspnoea, primarily 
opioids, were most often used for palliative care, as would be expected given the clinical 
pattern of end-stage respiratory disease (4,10,13,14).  
For most patients, the decision to reduce or restructure the CF regimen is made in a 
gradual way appropriate to the gradual decline in health. However, although our study lacks 
multivariate analysis and validated depression scales, its results also suggest that there are 
patients who discontinue the regimen out of despair or from a lack of familial and social 
support, at least according to the clinicians’ reporting. This is especially true for adolescents. 
It is worrying to see clinicians reporting that medication, which might be able to relieve 
symptoms, was stopped due to depression, feelings of abandonment, dysfunctional families 
or insufficient familial support. Psychiatric and social evaluation and support should therefore 
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be conducted. Palliative care services should be involved if appropriate, so that the regimen 
can be adjusted more explicitly to provide comfort.  
Recognising that a patient is in the final stages of life is an imprecise process in CF, 
requiring knowledge of the patient’s trajectory and response to previous interventions. Even 
experienced clinicians can be uncertain, and added to ethical considerations, that uncertainty 
may lead to difficulties in evaluating the burden of the treatment regimen. Our results suggest 
that a decrease in the clinical regimen, and acceptance of that modification by clinicians, may 
be a signal to begin a transition to a model of comfort care. This is likely to be especially true 
for patients that are free of major mood disorders, capable of judgement and receiving the 
appropriate familial and social support. Palliative care clinicians have long recognised that 
the expected trajectory of the illness strongly influences the timing of referral to palliative 
services (2,10,14), and that the standard model of palliative care, based on death from 
cancer, must be reconfigured to meet the needs of patients with CF (2,10,11,15).  
Our results reveal that some patients may struggle with the balance of hope and 
realism that characterises the life of a patient with severe disease due to CF. If psychiatric 
conditions like a major depressive disorder must be ruled out, it is important to keep in mind 
that despair and resignation are human responses to a severe and chronic illness for which 
there is no cure. As clinicians we have a duty of compassion to these patients at all stages of 
life. Acceptance that patients have changed their feelings about the usefulness of the 
treatments, and a more explicit permission to make such changes, may even become part of 
the compassionate response to the suffering of seriously ill people with CF.  
Finally, there seem to be patients that make the decision to cease treatment too 
soon, that is, when there is still an appreciable benefit expected from the point of view of 
comfort and survival length. Open discussion about the burden and benefits of the treatment 
may be helpful to these patients, and increasing psychosocial support accompanied by a 
temporarily flexible approach to adherence may help these patients to find their way back to 
an appropriate balance between the positive and negative aspects of treatment. Psychiatric 
conditions such as major depressive disorder should be referred to a psychiatrist for 
appropriate treatment. The decision to cease CF treatment in the context of insufficient 
familial support (nearly half of the adolescents in our sample) requires familial therapy or 
support. 
Only 102 patients of the 204 reported were eligible for analysis. This is why great 
care should be taken in interpreting these results. The trajectory of care in the final months of 
life with CF is variable, and the course and meaning of the adjustments made in the regimen 
cannot be perfectly discerned given our methodology. Our study only canvassed the views of 
clinicians, and only in a retrospective manner. Further work interviewing patients and family 
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members, as well as clinicians, would be able to uncover more precise differences among 
patients, as well as differences between care sites. 
In conclusion, our study highlights the existence of situations where CF patients 
decide to stop daily treatment because of feelings of hopelessness or futility of the treatment. 
It is worth mentioning that such situations are very challenging for all persons involved: the 
patient, the family and spouse, and also for members of the multi-disciplinary team, as such 
cases can be easily interpreted as a failure of their own competence. Facing such a complex 
situation, a clinician should be able to discuss the case with a multi-disciplinary team 
(including an ethical specialist) so that the most appropriate attitude is defined, from the 
active psychiatric treatment of a severely depressed person to the compassionate support of 
a patient with the ability to judge that it is no longer useful to combat CF. 
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Table 1: Completed surveys according to age and CF-association categories 
 
Number of completed patients Global Australia Europe USA
Total 102 15 16 71
Number of adults (18-more) 73 7 13 53
Number of adolescents (14-17) 25 8 2 15
Number of children (0-13) 4 0 1 3  
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Table 2: How, and which, treatments were stopped by the 102 CF patients 
 
Treatments stopped Global (n) Children (n) Adolescents (n) Adults (n)
all at once 29 1 5 23
progressively 73 3 20 50
1st treatment stopped°
Physiotherapy 21* 2 5** 14***
Antibiotics 16* 0 6** 10***
Vitamins 15* 1 5** 9***
Mucolytics 9* 0 1** 8***
Diet 6* 0 1** 5***
Pancreatic enzymes 1* 0 1** 0***
Others 1* 0 0** 1***
last treatment stopped°
Pancreatic enzymes 23* 1 6** 16***
Diet 18* 2 7** 9***
Antibiotics 14* 0 4** 10***
Mucolytics 5* 1 1** 1***
Physiotherapy 4* 0 1** 3***
Vitamins 4* 0 0** 4***
Others 0* 0 0** 0***
Resumption of treatment(s)
no 42 2 10 30
yes° 31 1 10 20
Antibiotics 19 1 5 13
Pancreatic enzymes 17 0 9 8
Physiotherapy 11 1 4 6
Diet 11 0 6 5
Mucolytics 6 0 2 4
Vitamins 2 0 1 1
Others 1 0 0 1  
The treatment was stopped progressively by 73/102 patients, of which 72/73 stopped one 
treatment after the other and 1/73 (listed in “Others”) diminished them all progressively. 
 
°= Multiple choice questions, (hence the numbers do not add up to the total respondents). 
Results are presented with regard to interpretable responses as follows: number of 
interpretable responses/all the responses: *= (63/72) **= (19/20) ***= (41/49) 
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Table 3: Use and type of palliative care treatments by the 102 CF patients 
 
Palliative care Global (n) Children (n) Adolescents (n) Adults (n)
No 32 1 6 25
Yes° 70 3 19 48
opioids 61 2 15 44
oxygen 60 1 16 43
anxiolytics 45 1 13 31
benzodiazepines 32 1 6 25
anti-nausea/anti-emetics 28 0 12 16
non-opioid analgesics 20 2 4 14
non-invasive ventilation 16 0 4 12
others 5 0 4 1
anti-spasmosodics/spasmolytics 1 0 0 1  
°= Multiple choice question, (hence the numbers do not add up to the total respondents). 
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Table 4: Reasons for stopping care by the CF 102 patients 
 
Reasons for stopping care° Global (n) Children (n) Adolescents (n) Adults (n)
Resignation 67 2 17 48
Enough is enough/discontent regarding the therapy 62 1 14 47
Reactive depression 39 1 10 28
Treatment
no 13 0 3 10
yes° 26 1 7 18
Antidepressants 22 1 5 16
Psychotherapy 23 0 7 16
Others 4 1 0 3
Therapy gives more suffering than benefits 37 2 9 26
Dysfunctional family and support 27 1 11 15
Feeling of being different, not able to live normally 20 1 9 10
Absence of social/professional perspectives 13 0 5 8
Feeling of being abandoned and fighting alone 11 0 4 7
Others 11 1 2 8
Other psychiatric disease(s) 6 0 2 4  
°= Multiple choice question, (hence the numbers do not add up to the total respondents). 
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Table 5: Main reason for stopping care by the 102 CF patients 
 
Main reason for stopping care Global (n) Children (n) Adolescents (n) Adults (n)
Resignation 29 0 6 23
Enough is enough/discontent regarding the therapy 25 0 7 18
Reactive depression 12 0 2 10
Dysfunctional family and support 11 1 6 4
Therapy gives more suffering than benefits 10 2 2 6
Feeling of being different, not able to live normally 5 0 1 4
Others 4 1 1 2
Other psychiatric disease(s) 3 0 0 3
Absence of social/professional perspectives 2 0 0 2
Feeling of being abandoned and fighting alone 1 0 0 1  
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